Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
August 04, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today...
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
August 01, 2023 09:30 ET
|
Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.”The patent covers a method for enhancing immune cell survival and...
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
July 28, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update...
Medicenna Presents at National Brain Tumor Society's Research Round Table
July 25, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”)The focus of the...
Medicenna Extends Period to Exercise Certain Warrants
July 05, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
June 27, 2023 08:00 ET
|
Medicenna Therapeutics Corp.
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a...
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
April 27, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
April 17, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues --...
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
March 30, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete...